Q2 Solutions Q2 Solutions Actionable Insights for Better Health and Lab Solutions
Factsheet
April 11, 2018

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium
Tumor mutational burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Q2 Solutions | EA Genomics offers a TMB assay, which utilizes a whole exome sequencing (WES) methodology and proprietary variant analysis compendium to enable sensitive mutation detection for quantifying TMB across various tumor indications.

Learn more about our TMB assay specifications and our comprehensive portfolio of genomic assays for immuno-oncology applications.

Related Services:
Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Global Flow Cytometry Services

Unique global flow cytometry services implemented with customizable solutions are designed to meet your clinical trial needs

Read More